Literature DB >> 9284132

Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies.

M Ho1, T Schollaardt, M D Smith, M B Perry, P J Brett, W Chaowagul, L E Bryan.   

Abstract

The lipopolysaccharide (LPS) of Burkholderia pseudomallei, the causative agent of melioidosis, consists of two O-antigenic polysaccharides designated O-PS I and O-PS II. In this study, the O-PS specificity and functional activity of a protective polyclonal antiserum and an immunoglobulin M (IgM) monoclonal antibody were determined. The polyclonal antiserum recognized both O-PS I and O-PS II, while the monoclonal antibody was O-PS II specific. Both mediated phagocytic killing of B. pseudomallei by polymorphonuclear leukocytes. Patients acutely infected with B. pseudomallei also produced antibodies to the two O-PSs, but these antibodies were not produced by asymptomatic individuals from an area of endemicity who were seropositive by an indirect hemagglutination test using sonicated heat-killed whole organisms as antigen. IgM antibodies were detected only in patients with localized infection. IgG antibodies were detected in all acutely infected patients, but there was no significant difference in antibody levels among patients with localized infection, patients who survived septicemic illness, and patients who died from septicemic illness. Further analysis of the IgG response revealed production of IgG1 and IgG2 antibodies by all patient groups, while an IgG3 response was seen only in survivors of septicemic infection. IgG4 was not detectable even when a fivefold-lower serum dilution was used. Patient sera also mediated phagocytic killing by polymorphonuclear leukocytes, and the killing effect was enhanced by complement. These results suggest that antibodies to the LPS O-polysaccharides of B. pseudomallei are protective by promoting phagocytic killing. The antibodies develop during human infection and may facilitate clearance of the organisms, as seen in a diabetic rat model of B. pseudomallei infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284132      PMCID: PMC175519          DOI: 10.1128/iai.65.9.3648-3653.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates.

Authors:  P J Brett; D E Woods
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement.

Authors:  A Aase; T E Michaelsen
Journal:  Scand J Immunol       Date:  1994-06       Impact factor: 3.487

3.  Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes.

Authors:  A M Egan; D L Gordon
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei.

Authors:  M B Perry; L L MacLean; T Schollaardt; L E Bryan; M Ho
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Intracellular survival of Burkholderia pseudomallei.

Authors:  A L Jones; T J Beveridge; D E Woods
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa.

Authors:  G B Pier; D M Thomas
Journal:  J Infect Dis       Date:  1983-08       Impact factor: 5.226

7.  Relapse in melioidosis: incidence and risk factors.

Authors:  W Chaowagul; Y Suputtamongkol; D A Dance; A Rajchanuvong; J Pattara-arechachai; N J White
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

8.  Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis.

Authors:  Y Suputtamongkol; A Rajchanuwong; W Chaowagul; D A Dance; M D Smith; V Wuthiekanun; A L Walsh; S Pukrittayakamee; N J White
Journal:  Clin Infect Dis       Date:  1994-11       Impact factor: 9.079

9.  Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in northeast Thailand.

Authors:  P Kanaphun; N Thirawattanasuk; Y Suputtamongkol; P Naigowit; D A Dance; M D Smith; N J White
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

10.  The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand.

Authors:  Y Suputtamongkol; A J Hall; D A Dance; W Chaowagul; A Rajchanuvong; M D Smith; N J White
Journal:  Int J Epidemiol       Date:  1994-10       Impact factor: 7.196

View more
  34 in total

1.  Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance.

Authors:  M N Burtnick; D E Woods
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 2.  Novel multi-component vaccine approaches for Burkholderia pseudomallei.

Authors:  L Morici; A G Torres; R W Titball
Journal:  Clin Exp Immunol       Date:  2019-04-08       Impact factor: 4.330

3.  Fate of a Burkholderia pseudomallei lipopolysaccharide mutant in the mouse macrophage cell line RAW 264.7: possible role for the O-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival.

Authors:  S Arjcharoen; C Wikraiphat; M Pudla; K Limposuwan; D E Woods; S Sirisinha; P Utaisincharoen
Journal:  Infect Immun       Date:  2007-06-18       Impact factor: 3.441

Review 4.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

5.  Revised structures for the predominant O-polysaccharides expressed by Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Christian Heiss; Mary N Burtnick; Rosemary A Roberts; Ian Black; Parastoo Azadi; Paul J Brett
Journal:  Carbohydr Res       Date:  2013-08-24       Impact factor: 2.104

Review 6.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  Use of Reverse Vaccinology in the Design and Construction of Nanoglycoconjugate Vaccines against Burkholderia pseudomallei.

Authors:  Laura A Muruato; Daniel Tapia; Christopher L Hatcher; Mridul Kalita; Paul J Brett; Anthony E Gregory; James E Samuel; Richard W Titball; Alfredo G Torres
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

8.  Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Authors:  Andrew E Scott; Thomas R Laws; Riccardo V D'Elia; Margaret G M Stokes; Tannistha Nandi; E Diane Williamson; Patrick Tan; Joann L Prior; Timothy P Atkins
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

9.  Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis.

Authors:  Vidhya Novem; Guanghou Shui; Dongling Wang; Anne K Bendt; Siew Hoon Sim; Yichun Liu; Tuck Weng Thong; Suppiah Paramalingam Sivalingam; Eng Eong Ooi; Markus R Wenk; Gladys Tan
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

10.  Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization.

Authors:  Stephen J Elvin; Gareth D Healey; Angie Westwood; Stella C Knight; James E Eyles; E Diane Williamson
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.